Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001090 | 1.00 | KCNQ2 (0.57) | KCNQ2KCNQ3 | |
| SCHEMBL14846478 | 0.91 | KCNQ2 (0.61) | KCNQ2KCNQ3 | |
| SCHEMBL30814196 | 0.90 | KCNQ2 (0.60) | KCNQ2KCNQ3 | |
| SCHEMBL1000859 | 0.90 | KCNQ2 (0.60) | KCNQ2KCNQ3 | |
| SCHEMBL12926913 | 0.90 | KCNQ2 (0.62) | KCNQ2KCNQ3 | |
| SCHEMBL1000192 | 0.90 | KCNQ2 (0.73) | KCNQ2KCNQ3 | |
| SCHEMBL30814264 | 0.90 | KCNQ2 (0.59) | KCNQ2KCNQ3 | |
| SCHEMBL30795009 | 0.90 | KCNQ2 (0.67) | KCNQ2KCNQ3 | |
| SCHEMBL1000323 | 0.90 | KCNQ2 (0.67) | KCNQ2KCNQ3 | |
| SCHEMBL1000265 | 0.90 | KCNQ2 (0.59) | KCNQ2KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |